
How RSV manipulates the immune response in respiratory cells
TWINCORE researchers investigate gene activity in host cells

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
This year's TWINCORE Symposium will take place on 3 - 4 September.

TWINCORE researchers investigate gene activity in host cells

Diverse Origins – One Goal

The 23rd doctoral thesis to receive an award at TWINCORE
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Vandenabeele L, Ayanwale A, Pietschmann T, Nilsson-Payant B
Dinkelborg K, Niehaus C, Bremer B, Wundes C, Tiede A, Petruch N, Deterding K, Kraft A, Hartleben B, Cornberg M, Wedemeyer H, Behrendt P, Maasoumy B
Berg K, Haid S, Vafadarnejad E, Carpentier A, Geffers R, Wiegmann B, Saliba A, Erhard F, Pietschmann T
Immunomodulatory drugs for rheumatic diseases specifically influence immune cells and messenger substances. This project investigates their effect on immune responses in order to find individually suitable therapies.
Immunomodulatory drugs can have systemic side effects. This project is testing nanocarriers that deliver drugs specifically into myeloid immune cells in order to reduce side effects and increase the local effect.
In collaboration with the Department of Neurology and the Metabolomics Department, the project is investigating metabolic products in cerebrospinal fluid in order to identify biomarkers for CNS infections and cell damage and to distinguish long COVID and viral from autoimmune diseases.
Older people are at high risk of a poor immune response to the flu vaccine. Together with partners, we are looking for biomarkers and risk factors for this inadequate response and are investigating ways to improve the vaccination response.

